Debrisoquin (hydrobromide)
Debrisoquine (Ro 5-3307/1) hydrobromide is a TMPRSS2 inhibitors that inhibits SARS-CoV-2 entry into human lung cell line by a TMPRSS2-depedent manner, with an IC50 of 22μM. Debrisoquine hydrobromide can be used for antiviral research[1].
Product Specifications
CAS Number
[1131-65-3]
Product Name Alternative
Debrisoquine (hydrobromide) ; Isocaramidine (hydrobromide) ; Ro 5-3307/1 (hydrobromide)
UNSPSC
12352005
Target
SARS-CoV; Ser/Thr Protease
Related Pathways
Anti-infection; Metabolic Enzyme/Protease
Applications
COVID-19-anti-virus
Field of Research
Infection
Smiles
N=C(N1CC2=C(CC1)C=CC=C2)N.Br
Molecular Formula
C10H14BrN3
Molecular Weight
256.14
References & Citations
[1]Amanda L. Peiffer, et.al.TMPRSS2 Inhibitor Discovery Facilitated through an In Silico and Biochemical Screening Platform.ACS Medicinal Chemistry Letters 2023 14 (6), 860-866.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
GTR15347712 1 Vial
Lentiviral human FYB2 shRNA (UAS) - Lentiviral human FYB2 shRNA (UAS, GFP) (100)
Ask
View Details 
H9117-83T-HRP 200 µL
Hydroxysteroid Dehydrogenase, 17-beta 7, NT, (Hydroxysteroid (17-beta) Dehydrogenase 7, HSD17B7, 17-beta-hydroxysteroid Dehydrogenase 7, 17-beta-HSD 7, 3-Keto-steroid Reductase, Estradiol 17-beta-dehydrogenase 7, MGC12523, MGC75018, PRAP, SDR37C1, UNQ2563/PRO6243) (HRP) discontinued
Ask
View Details